Logan Capital Management Inc. Cuts Holdings in Becton, Dickinson and Company $BDX

Logan Capital Management Inc. reduced its stake in Becton, Dickinson and Company (NYSE:BDX) by 9.8% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,444 shares of the medical instruments supplier’s stock after selling 156 shares during the quarter. Logan Capital Management Inc.’s holdings in Becton, Dickinson and Company were worth $249,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Saudi Central Bank bought a new position in Becton, Dickinson and Company in the 1st quarter worth $26,000. Smallwood Wealth Investment Management LLC bought a new stake in Becton, Dickinson and Company during the first quarter valued at about $27,000. Cornerstone Planning Group LLC raised its holdings in Becton, Dickinson and Company by 341.4% during the first quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier’s stock valued at $29,000 after acquiring an additional 99 shares during the period. Kelly Lawrence W & Associates Inc. CA bought a new stake in Becton, Dickinson and Company during the first quarter valued at about $31,000. Finally, WPG Advisers LLC bought a new stake in Becton, Dickinson and Company during the first quarter valued at about $36,000. 86.97% of the stock is owned by institutional investors.

Insider Buying and Selling at Becton, Dickinson and Company

In related news, Director Claire Fraser sold 917 shares of the stock in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total transaction of $171,937.50. Following the completion of the transaction, the director owned 22,226 shares of the company’s stock, valued at approximately $4,167,375. This trade represents a 3.96% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Over the last three months, insiders have sold 1,895 shares of company stock valued at $358,995. Corporate insiders own 0.36% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have commented on BDX. Morgan Stanley raised their price target on Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an “overweight” rating in a report on Monday, August 11th. Argus raised their price target on Becton, Dickinson and Company from $220.00 to $230.00 in a report on Monday, September 15th. Piper Sandler reissued a “neutral” rating and set a $200.00 price target (up from $185.00) on shares of Becton, Dickinson and Company in a report on Friday, August 8th. Weiss Ratings restated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research report on Wednesday, October 8th. Finally, Wall Street Zen upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. Three analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Becton, Dickinson and Company presently has a consensus rating of “Hold” and a consensus target price of $205.40.

Becton, Dickinson and Company Stock Performance

Shares of BDX stock opened at $184.35 on Wednesday. The company has a market cap of $52.84 billion, a PE ratio of 33.16, a PEG ratio of 1.46 and a beta of 0.25. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a 12-month low of $163.33 and a 12-month high of $251.99. The business’s fifty day simple moving average is $189.49 and its 200-day simple moving average is $183.53.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, April 14th. The medical instruments supplier reported $4.10 EPS for the quarter. The company had revenue of $5.32 billion during the quarter. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. Analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.